Clonazepam (Psy and Mixed indications) updated on 02-10-2025

Ano-rectal atresia and stenosis

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15651
R64621
Blotière (Indications other than epilepsy), 2019 Anorectal atresia 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.76 [0.11;28.16] C 0/980   544/1,875,733 544 980
ref
S15601
R64297
Tinker (Mixed indications), 2019 Anorectal atresia/stenosis 1st trimester case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) 1.03 [0.24;4.40] C 2/23   1,064/12,576 1,066 23
ref
S17865
R75465
Eros (Indications NOS), 2002 Rectal–anal atresia/stenosis during pregnancy (anytime or not specified) excluded case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched no data
excluded (exposition period)
0/-   -/- - -
ref
Total 2 studies 1.16 [0.32;4.18] 1,610 1,003
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Indications other than epilepsy), 2019Blotière, 2019 1 1.76[0.11; 28.16]54498022%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Tinker (Mixed indications), 2019Tinker, 2019 2 1.03[0.24; 4.40]1,0662378%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Total (2 studies) I2 = 0% 1.16[0.32; 4.18]1,6101,0030.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Indications other than epilepsy; 2: Mixed indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.76[0.11; 28.16]544980 -NABlotière (Indications other than epilepsy), 2019 1 case control studiescase control studies 1.03[0.24; 4.40]1,06623 -NATinker (Mixed indications), 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.16[0.32; 4.18]1,6101,0030%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 Tags Adjustment   - No  - No 1.16[0.32; 4.18]1,6101,0030%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 2 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.76[0.11; 28.16]544980 -NABlotière (Indications other than epilepsy), 2019 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 1.03[0.24; 4.40]1,06623 -NATinker (Mixed indications), 2019 1 All studiesAll studies 1.16[0.32; 4.18]1,6101,0030%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.16[0.32; 4.18]1,6101,0030%NABlotière (Indications other than epilepsy), 2019 Tinker (Mixed indications), 2019 20.510.01.0